[1]
A. Neelam and A. Kanaki, “Efficacy and safety of remogliflozin etabonate in type 2 diabetes mellitus patients in a tertiary care hospital”, Int J Basic Clin Pharmacol, vol. 10, no. 4, pp. 353–356, Mar. 2021.